Ads
related to: mannkind news clinical trials this week
Search results
Results From The WOW.Com Content Network
MannKind (NAS: MNKD) announced breathtaking news this week -- literally. The biotech completed patient recruitment for two phase 3 clinical trials for its insulin inhalant Afrezza. The ...
MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (Nasdaq: MNKD) today announced that all follow-up ...
Today, MannKind announced that its two Phase 3 Afrezza clinical trials have completed patient enrollment, and this will help the company stay on track to file for FDA approval in Q3 of 2013.
MannKind Completes Patient Recruitment in Two Phase 3 Clinical Studies of AFREZZA VALENCIA, Calif.--(BUSINESS WIRE)-- MannKind Corporation (Nasdaq: MNKD) today announced that it has completed ...
Biopharmaceutical company MannKind (NAS: MNKD) is seeking FDA approval for its inhalable insulin drug, Afrezza. A decision in 2013 is expected, and the company hopes to get this drug to market as ...
After seeing MannKind rocket upwards over the last week, Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to chat about what's going on with the inhaled ...
The small steps are largely behind biotech company MannKind (NAS: MNKD) . Over the course of the past few years, the company navigated 61 different clinical studies for its Afrezza insulin ...
MannKind took one giant leap over the past few days. Shares have soared more than 30% since last week, after the company reported results for the first quarter. Was the news that great? Not really.